Cargando…
The changing treatment landscape in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487773/ https://www.ncbi.nlm.nih.gov/pubmed/25726557 http://dx.doi.org/10.1183/09059180.00011414 |
_version_ | 1784792517249597440 |
---|---|
author | Costabel, Ulrich |
author_facet | Costabel, Ulrich |
author_sort | Costabel, Ulrich |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. |
format | Online Article Text |
id | pubmed-9487773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94877732022-11-14 The changing treatment landscape in idiopathic pulmonary fibrosis Costabel, Ulrich Eur Respir Rev Reviews Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. European Respiratory Society 2015-03 /pmc/articles/PMC9487773/ /pubmed/25726557 http://dx.doi.org/10.1183/09059180.00011414 Text en Copyright ©ERS 2015. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Reviews Costabel, Ulrich The changing treatment landscape in idiopathic pulmonary fibrosis |
title | The changing treatment landscape in idiopathic pulmonary fibrosis |
title_full | The changing treatment landscape in idiopathic pulmonary fibrosis |
title_fullStr | The changing treatment landscape in idiopathic pulmonary fibrosis |
title_full_unstemmed | The changing treatment landscape in idiopathic pulmonary fibrosis |
title_short | The changing treatment landscape in idiopathic pulmonary fibrosis |
title_sort | changing treatment landscape in idiopathic pulmonary fibrosis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487773/ https://www.ncbi.nlm.nih.gov/pubmed/25726557 http://dx.doi.org/10.1183/09059180.00011414 |
work_keys_str_mv | AT costabelulrich thechangingtreatmentlandscapeinidiopathicpulmonaryfibrosis AT costabelulrich changingtreatmentlandscapeinidiopathicpulmonaryfibrosis |